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Spiranthera odoratissimaSpiranthera odoratissima A. St. Hil. (manacá) is used in folk medicine to treat renal and hepatic diseases, stom-
achache, headaches and rheumatism. A central nervous system (CNS) depressant effect of the hexane fraction
from the ethanolic extract of this plant has been described. β-caryophyllene, the main component of this es-
sential oil, is a sesquiterpene compound with anti-inﬂammatory properties that has been found in essential
oils derived from several medicinal plants.
This work is aimed to evaluate the pharmacological activity of the essential oil obtained from S. odoratissima
leaves (EO) and its major component on the murine CNS; we aimed to evaluate a possible anxiolytic-like ef-
fect and the underlying mechanisms involved. In an open ﬁeld test, EO (500 mg/kg) and β-caryophyllene (50,
100 and 200 mg/kg) increased the crossing frequency (Pb0.05) and, EO (250 and 500 mg/kg) and β-
caryophyllene (200 mg/kg) increased the time spent in the center (Pb0.05) without altering total crossings
of the open ﬁeld. EO and β-caryophyllene did not alter the number of falls in the rota-rod test (P>0.05). In the
pentobarbital-induced sleep test, EO (500 mg/kg) and β-caryophyllene (200 and 400 mg/kg) decreased the laten-
cy to sleep (Pb0.05), and EO (125, 250 and 500 mg/kg) (Pb0.001) and β-caryophyllene (200 and 400 mg/kg)
(Pb0.05 and Pb0.001) increased the sleep time. In anxiety tests, EO (500 mg/kg) and β-caryophyllene (100 and
200 mg/kg) increased head-dipping behavior (Pb0.05) in the hole-board test, entries (Pb0.05) into and time
spent (Pb0.05) on the open arms of the elevated plus maze (EPM), and number of transitions (Pb0.05) and
time spent in the light compartment (Pb0.05) of a light–dark box (LDB). We further investigated the mechanism
of action underlying the anxiolytic-like effect of EO and β-caryophyllene by pre-treating animals with antagonists
of benzodiazepine (ﬂumazenil) and 5-HT1A (NAN-190) receptors prior to evaluation using EPM and LDB. The
anxiolytic-like effects of EOwere signiﬁcantly reduced by pre-treatmentwith NAN-190 (Pb0.05) but not ﬂumaze-
nil (P>0.05). The anxiolytic-like effects of β-caryophyllene were not blocked by either NAN-190 or ﬂumazenil
(P>0.05). In conclusion, these results suggest that the essential oil derived from S. odoratissima produces an
anxiolytic-like effect without altering motor performance and that this effect is mediated by 5-HT1A but not via
benzodiazepine receptors. In addition, the major component, β-caryophyllene, also has an anxiolytic-like effect
thatmay contribute to the effects of EO, but this effect does not seem to bemediated via 5-HT1A or benzodiazepine
receptors.
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Anxiety and stress disorders are among the most common of all
chronic diseases. The prevalences of these disorders are increasing
in many countries, and these disorders have a much earlier age of
onset than other chronic conditions (Kessler and Greenberg, 2002).
As an example, in Brasilia city (the capital of Brazil), anxiety disorders
affect 12.1% of the population and are the most commonly diagnosed
psychiatric disorders (Almeida Filho et al., 1992).
Since the introduction of benzodiazepines in the 1960s, they have
been the most commonly prescribed treatment for anxiety, remaining
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ever, they have prominent side effects, such as sedation, myorelaxation,
ataxia, and amnesia, and they can cause pharmacological dependence
(Lader and Morton, 1991). Thus, new therapies for the treatment of
anxiety disorders are necessary, and the study of medicinal plants
could provide new therapeutic options (Faustino et al., 2010).
The anxiolytic-like effect of plants from Rutaceae family has al-
ready been demonstrated; such plants include Citrus aurantium L.
(Carvalho-Freitas and Costa, 2002), Casimiroa edulis La Llave ex Lex.
(Molina-Hernández et al., 2004; Mora et al., 2005) and Ruta chalepen-
sis L. (Gonzalez-Trujano et al., 2006).
Spiranthera odoratissima A. St. Hillaire (Rutaceae) is a shrub that is
found in the Brazilian Cerrado region and popularly known in Brazil
asmanacá. Its ﬂowers are whitish and very aromatic, its fruits possess
a unique seed and its roots are woody, with yellow-gold coloration
(Almeida et al., 1998). In folk medicine, its leaves are used as a
blood purgative and in the treatment of renal and hepatic diseases
(Salles et al., 1997), while the roots are used to as an appetite stimu-
lant and to treat stomachache, headaches, sore muscles, and hepatic
dysfunction (Silva, 1998). In the state of Goiás, Brazil, these roots
are also used to treat rheumatism (Tresvenzol et al., 2006).
According to Matos et al. (2003), the aqueous fraction from the
ethanolic extract of manacá leaves shows analgesic and anti-
inﬂammatory activities in the acetic acid-induced writhing, croton
oil-induced ear edema and carrageenan-induced peritonitis models.
Similar results were obtained with the ethanolic extract of manacá
roots, which are also characterized by the central nervous system de-
pressant activity (Matos et al., 2004). The evaluation of the effects of
the hexane fraction from the ethanolic extract of S. odoratissima
leaves on the murine CNS indicates that this fraction has active sub-
stances that increase the sleep time in a pentobarbital-induced
sleep test (Matos et al., 2006).
β-Caryophyllene, the major component of S. odoratissima essential
oil (Chaibub and Paula, 2009), is a sesquiterpene compound found in
the essential oils of many different species (Gertsch et al., 2008;
Molina-Jasso et al., 2009). Among the pharmacological activities of
this compound are anti-inﬂammatory (Fernandes et al., 2007;
Medeiros et al., 2007; Passos et al., 2006) and antispasmodic activities
(Leonhardt et al., 2010); it has also been used as a local anesthetic
(Ghelardini et al., 2001) and gastric cytoprotector (Tambe et al.,
1996), to stimulate natural killer cells (Standen et al., 2006). It has
also been shown to be neuroprotective in human neuroblastoma
(Chang et al., 2007).
Then, this work is aimed to evaluate the neuropharmacological ac-
tivity of the essential oil from S. odoratissima leaves in the CNS, with
special attention to possible anxiolytic-like effects, as well as the
roles of 5HT1A and GABAA/benzodiazepine receptors in these effects.
The identiﬁcation of the active component(s) is one step in the pro-
posed development of an herbal drug; therefore, this paper includes
examination of the anxiolytic-like effect and possible mechanism of
action of the essential oil's major compound, β-caryophyllene.
2. Material and methods
2.1. Animals
Male adult Swiss mice weighing approximately 30 g (n=765)
were used in all experiments. All animals were used only once. The
animals were provided by the Central Animal House of Federal Uni-
versity of Goiás (Universidade Federal de Goiás — UFG); they were
housed in groups of 20 mice/cage and were kept in a room with con-
trolled temperature (25±1 °C) and lighting (light/dark cycle of 12 h,
lights on at 7 am), with food and water ad libitum. The animals were
kept in the laboratory for an adaptation period of at least 1 h before
the experiments. All experimental protocols were developed in accor-
dance with the principles of ethics and animal welfare recommendedby Brazilian Science Society of Laboratory Animal (Sociedade Brasi-
leira de Ciência em Animais de Laboratório) and were approved by
the UFG Institutional Ethical Committee (Protocol 104/2008).
2.2. Plant material and essential oil extraction
S. odoratissima A. St.-Hil. leaves were collected in December 2007
near the town of Senador Canedo, Goiás, Brazil (762 m, 16°45′45.2″ S,
49°07′06.8″ W) and were authenticated by Prof. Dr. José Realino de
Paula (Pharmacy Faculty — UFG). A voucher specimen was deposited
at the Herbarium of the UFG (UFG — 30,275). The leaves were dried at
room temperature and crushed, and the essential oil (EO)was extracted
by hydrodistillation for approximately 3 h using a Clavenger-type appa-
ratus,with a yield of 2.3%. The EOwas subjected to gas chromatographic
mass spectrometry in SHIMADZU QP5050A equipment, and the chemi-
cal components were identiﬁed by comparing themass spectra and the
retention indexes with the literature. The major components identiﬁed
were β-caryophyllene (20.64%), gamma-muurolene (17.7%), bicyclo-
germacrene (14.73%), delta-cadinene (13.40%), gamma-cadinene
(4.59%) and cubenol (3.12%) (Chaibub and Paula, 2009).
2.3. Drugs
EO and β-caryophyllene (Sigma — Brazil) were emulsiﬁed with
2% Tween 80 (Sigma— USA) and dissolved in distilled water. Sodium
pentobarbital (Abbott — Brazil) was dissolved in saline. Diazepam
(Cristália — Brazil) was dissolved in distilled water. It is well
known that benzodiazepines act as anxiolytics at low doses and
that they induce sedation and myorelaxant effects at higher doses
(Novas et al., 1988). Therefore, we used diazepam (1 mg/kg) as a
positive control for anxiolytic-like effects, and diazepam (5 mg/kg)
as a positive control for sedative andmyorelaxant effects. Flumazenil
(União Química — Brazil) and NAN-190 (1-(2-methoxyphenyl)-4-
[4-(2-phthalimido) butyl] piperazine hydrobromide — Sigma —
USA) were used as pretreatments to verify the role of GABAA/benzo-
diazepine and 5-HT1A receptors, respectively.
2.4. Behavioral procedures
2.4.1. General behavior test
Experimental groups of mice (n=5 per group) were treated orally
(p.o.), intraperitoneally (i.p.) or subcutaneously (s.c.) with OE at
doses of 10, 30, 100, 300 or 1000 mg/kg or with β-caryophyllene at
doses of 50, 100 or 200 mg/kg, whereas control groups received vehi-
cle (2% Tween 80 in distilled water, 10 mL/kg) by the same routes.
The animals were observed in free ambulation on a ﬂat surface for
3 min, again at 5, 10, 20, 30 and 60 min, and 4, 8, 24 and 48 h after
the treatments and after 4 and 7 days of treatment. The observed ef-
fects were noted using a standard pharmacological screening ap-
proach, adapted from Malone (1977).
2.4.2. Rota-rod test
In this test, the animals were pre-selected in a training session
24 h before the test based on their ability to remain on the bar (at
12 rpm) for 2 min. Groups of pre-selected animals (n=9) were trea-
ted (p.o.) with vehicle (2% Tween 80, 10 mL/kg), EO (125, 250 or
500 mg/kg), β-caryophyllene (50, 100, 200 or 400 mg/kg) or diaze-
pam (1 or 5 mg/kg). Sixty minutes after the treatment, the animals
were placed with all four paws onto the bar and the number of falls
was evaluated. The maximum time allowed was 1 min, and the max-
imum number of falls allowed was three (Dunham and Miya, 1957).
2.4.3. Open-ﬁeld test
Experimental groups of 9micewere treated (p.o.) with vehicle (2%
Tween 80, 10 mL/kg), EO (125, 250 or 500 mg/kg), β-caryophyllene
(50, 100 or 200 mg/kg) or diazepam (1 or 5 mg/kg). Sixty minutes
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ﬁeld arena made of clear Plexiglas in which the bottom was divided
into eight areas; the observed parameters were as follows: total num-
ber of crossings, central area crossings, time spent in central area, rear-
ing and grooming behaviors and fecal bolus (Archer, 1973; Siegel,
1946).
2.4.4. Pentobarbital-induced sleep test
Experimental groups of 9micewere treated (p.o.) with vehicle (2%
Tween 80, 10 mL/kg), EO (125, 250 or 500 mg/kg), β-caryophyllene
(50, 100, 200 or 400 mg/kg) or diazepam (1 or 5 mg/kg). Sixty mi-
nutes after the treatment, the animals received sodium pentobarbital
(50 mg/kg i.p.), and the time elapsed between the administration of
pentobarbital until the loss of the righting reﬂex was recorded as the
sleep latency, and the time elapsed between the loss and voluntary re-
covery of the righting reﬂex was recorded as the sleep time (Carlini
and Burgos, 1979).
2.4.5. Hole-board test
Experimental groups of 9micewere treated (p.o.) with vehicle (2%
Tween 80, 10 mL/kg), EO (125, 250 or 500 mg/kg), β-caryophyllene
(50, 100 or 200 mg/kg) or diazepam (1 or 5 mg/kg). Sixty minutes
after treatment, the animals were placed into the center of a perforat-
ed boardwith the bottom divided into nine squares of equal areas; the
number of head-dips into the holes and the number of squares crossed
(with all four paws) were recorded over a 5 min period (Clark et al.,
1971).
2.4.6. Elevated plus maze test
Experimental groups of 9micewere treated (p.o.) with vehicle (2%
Tween 80, 10 mL/kg), EO (125, 250 or 500 mg/kg), β-caryophyllene
(50, 100 or 200 mg/kg) or diazepam (1 or 5 mg/kg). Sixty minutes
after treatment, the animals were individually placed at the center of
a plus maze (purchased from Insight Scientiﬁc Equipment — Brazil)
and observed for 5 min (Lister, 1987; Pellow et al., 1985). The test oc-
curred under a red light and was fully recorded for later analysis,
which consisted of counting the number of entries into the open and
enclosed arms and the time spent by the animal in the open and
enclosed arms. The number of entries into and time spent in the
open arms was later converted into percentage of total entries and
time, respectively, and these percentages were used as a measure of
anxiety. (Anxiolytic compounds reduce the animal's aversion to the
open arms and promote the exploration thereof.)
2.4.7. Light–dark box test
Experimental groups of 9micewere treated (p.o.) with vehicle (2%
Tween 80, 10 mL/kg), EO (125, 250 or 500 mg/kg), β-caryophyllene
(50, 100 or 200 mg/kg) or diazepam 1 or 5 mg/kg. Sixty minutes
after treatment, the animals were placed in the center of the light
area facing the dark area opening; the number of transitions between
the two compartments and the time spent in the light area were
recorded over a 5 min period (Crawley and Goodwin, 1980).
2.4.8. Mechanisms involved in the anxiolytic-like activities of EO and
β-caryophyllene
To investigate the possible mechanisms underlying the anxiolytic
activities of EO and β-caryophyllene, the animals were intraperitone-
ally pre-treated with ﬂumazenil (6 mg/kg; 15 min pre-treatment), an
antagonist of GABAA/benzodiazepine receptors (Savić et al., 2004) or
NAN-190 (0.5 mg/kg; 30 min pre-treatment), an antagonist of 5-HT1A
receptors (Huo et al., 2010).
2.5. Statistical analysis
The results were expressed as the means±standard errors of the
mean (SEM). Signiﬁcant differences between experimental groupswere detected by one-way ANOVA (analysis of variance) followed
by Student–Newman–Keuls test (more than two groups), or unpaired
Student's t test (two groups). The results without normal distribution
were analyzed using Kruskal–Wallis's test followed by Dunn's test.
Effects were considered signiﬁcant at P≤0.05.
3. Results
3.1. General behavioral testing
Upon subcutaneous administration of EO (300 and 1000 mg/kg), de-
creases in spontaneous ambulations (10–20 min and 10–60 min, re-
spectively) and environmental alienations (10–20 min and 10–30 min,
respectively) were observed; with EO (1000 mg/kg) palpebral ptosis
(20–60 min) and analgesia (10–30 min) were observed. Upon intraperi-
toneal administration of EO (100, 300 and 1000 mg/kg), a decrease
in spontaneous ambulations (60min, 10–60 min, and 5 min–4 h, re-
spectively) were observed; with EO (300 and 1000 mg/kg) analgesia
(30–60 min and 10–60 min, respectively) and environmental alienations
(both at 30–60 min) were also observed. Only at the 1000 mg/kg dose
abdominal writhing (at 10 min) and one death (within 8 h of the treat-
ment) were observed. Among the oral treatments, only the 1000 mg/kg
dose decreased the animals' spontaneous ambulation (60 min) and
induced analgesia (20–60 min). Upon intraperitoneal administration of
β-caryophyllene (200 mg/kg), abdominal writhing was observed at
30–60 min and 24 h. No other alterations were observed upon subcuta-
neous, intraperitoneal or oral treatment with β-caryophyllene at the
doses we evaluated.
3.2. Rota-rod test
Neither EO nor β-caryophyllene (at any dose) altered the number
of falls in the rota-rod test, whereas diazepam (at 5 mg/kg only) sig-
niﬁcantly increased the number of falls, as expected [KW=30.83,
Pb0.001; Dunn, Pb0.001 vs. vehicle group, Table 1].
3.3. Open-ﬁeld test
Treatment (p.o.) with EO, β-caryophyllene and diazepam did not
alter grooming behavior [ANOVA: F(8,72)=0.8482, P>0.05]; the total
number of crossings [ANOVA: F(8,72)=9.874, Pb0.001] was reduced
only by diazepam (5 mg/kg) (Pb0.001 vs. vehicle). The fecal bolus
[ANOVA: F(8,72)=15.533, Pb0.001] was reduced by p.o. treatment
with EO (125, 250 and 500 mg/kg) (Pb0.05, Pb0.05 and Pb0.001 vs. ve-
hicle group, respectively) and diazepam (1 and 5 mg/kg) (Pb0.05 and
Pb0.001 vs. vehicle group, respectively), while β-caryophyllene treat-
ment did not alter this parameter (P>0.05 vs. vehicle group). The num-
ber of central area crossings [ANOVA: F(8,72)=15.473, Pb0.001] was
increased by EO (500 mg/kg) (Pb0.001 vs. vehicle), β-caryophyllene
(50, 100 and 200 mg/kg) (Pb0.05, Pb0.05 and Pb0.01 vs. vehicle
group, respectively) and diazepam (1 mg/kg) (Pb0.01 vs. vehicle),
while diazepam(5 mg/kg) reduced this parameter (Pb0.001 vs. vehicle).
Rearing behavior [ANOVA: F(8,72)=32.450, Pb0.001]was decreased by
EO (500 mg/kg) (Pb0.05 vs. vehicle) and diazepam (5 mg/kg) (Pb0.001
vs. vehicle), while β-caryophyllene had no effect (P>0.05 vs. vehicle).
The time spent in the central area [ANOVA: F(8,72)=21.855, Pb0.001]
was increased by EO (500 and 250 mg/kg) (Pb0.05 and Pb0.001 vs. ve-
hicle, respectively), β-caryophyllene (200 mg/kg) (Pb0.05 vs. vehicle)
and diazepam (1 mg/kg) (Pb0.001 vs. vehicle), while diazepam
(5 mg/kg) reduced this parameter (Pb0.05 vs. vehicle) (Table 2).
3.4. Pentobarbital-induced sleep test
The sleep latency [ANOVA: F(9,80)=8.628, Pb0.001; Fig. 1A] was
decreased by p.o. treatment with EO (500 mg/kg) (Pb0.05 vs. vehi-
cle), β-caryophyllene (200 and 400 mg/kg) (Pb0.05 and Pb0.05 vs.
Table 1
Effects of essential oil from Spiranthera odoratissima leaves
(EO) and β-caryophyllene on the rota rod test.
Groups Number of falls
Vehicle 0.2±0.15
EO 125 0.4±0.20
EO 250 0.6±0.27
EO 500 0.6±0.27
β-car 50 0.1±0.26
β-car 100 0.1±0.31
β-car 200 0.4±0.52
β-car 400 0.2±0.42
Dzp 1 0.6±0.70
Dzp 5 2.3±0.31♦♦♦
Data expressed asmean±SEMof ninemice. Vehicle (2% Tween,
10mL/kg, p.o.), EO: essential oil from Spiranthera odoratissima
leaves (125, 250 and 500mg/kg, p.o.), β-caryophyllene (100,
200 and 400mg/kg, p.o.) and DZP: diazepam (1 and 5mg/kg,
p.o.).
♦♦♦ P≤0.001 compared with control group using Kruskal–
Wallis's test and Dunn's test as the post hoc test.
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Fig. 1. Effect of essential oil (EO) from Spiranthera odoratissima leaves and β-
caryophyllene on the sleep latency, in seconds (A) and sleeping time, in minutes (B),
of the pentobarbital-induced sleep test in mice. Vehicle (V, 2% Tween 80, 10 mL/kg
p.o.), essential oil (EO, 125, 250 or 500 mg/kg p.o.), β-caryophyllene (50, 100, 200 or
400 mg/kg p.o.) and diazepam (DZP, 1 or 5 mg/kg p.o.). The columns and vertical
bars represent the means±SEM of nine mice. *P≤0.05, **P≤0.01, ***P≤0.001 com-
pared with control group using ANOVA and Student–Newman–Keuls test as the post
hoc test.
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Pb0.001 vs. vehicle, respectively). The sleeping time [ANOVA:
F(9,80)=128.53, Pb0.001; Fig. 1B] was increased by EO (125, 250
and 500 mg/kg) (Pb0.001, Pb0.001 and Pb0.001 vs. vehicle, respec-
tively), β-caryophyllene (200 and 400 mg/kg) (Pb0.05 and Pb0.001
vs. vehicle, respectively), and diazepam (1 and 5 mg/kg) (Pb0.001
and Pb0.001 vs. vehicle, respectively).
3.5. Hole-board test
Head-dipping behavior [F(8,72)=14.058, Pb0.001; Fig. 2A] was
increased by p.o. treatment with EO (250 and 500 mg/kg) (Pb0.01
and Pb0.05 vs. vehicle, respectively), β-caryophyllene (100 and
200 mg/kg) (Pb0.05 and Pb0.05 vs. vehicle, respectively) and diaze-
pam (1 mg/kg) (Pb0.05 vs. vehicle), while diazepam (5 mg/kg) re-
duced head-dipping behavior (Pb0.05 vs. vehicle). With regard to
the number of squares crossed [ANOVA: F(8,72)=5.522, Pb0.001;
Fig. 2B], only diazepam (5 mg/kg) reduced this parameter (Pb0.01
vs. vehicle).
3.6. Elevated plus maze test
The number of entries into the open arms [ANOVA: F(8,72)=8.777,
Pb0.001; Fig. 3A] was increased by p.o. treatmentwith EO (500 mg/kg)
(Pb0.01 vs. vehicle), β-caryophyllene (100 and 200 mg/kg) (Pb0.05
and Pb0.05 vs. vehicle, respectively) and diazepam (1 mg/kg)
(Pb0.01 vs. vehicle group), while diazepam (5 mg/kg) reduced this pa-
rameter (Pb0.05 vs. vehicle group). The time spent in the open armsTable 2
Effects of essential oil from Spiranthera odoratissima leaves (EO) on the open-ﬁeld test.
Groups Open ﬁeld test parameters
Total crossing Central area crossing (%) Time spent i
Vehicle 97.9±5.15 50.1±3.36 118.1±8.77
EO 125 106.0±7.62 52.1±3.01 114.3±8.31
EO 250 97.9±6.99 53.0±1.45 155.2±10.6
EO 500 85.3±9.59 68.6±2.90⁎⁎⁎ 214.1±10.5
β-car 50 103.5±5.57 61.9±1.89⁎ 135.7±7.25
β-car 100 94.6±5.71 59.7±1.95⁎ 121.2±7.03
β-car 200 112.9±7.15 65.2±2.17⁎⁎ 158.6±8.68
Dzp 1 130.89±7.56⁎ 62.2±2.30⁎⁎ 167.5±12.9
Dzp 5 51.6±5.18⁎⁎⁎ 36.4±2.19⁎⁎⁎ 52.4±10.3
Data expressed as mean±SEM of nine mice. Vehicle (2% Tween, 10 mL/kg, p.o.), EO: esse
β-caryophyllene (50, 100 and 200 mg/kg, p.o.), DZP: diazepam (1 and 5 mg/kg, p.o.).
⁎⁎⁎P≤0.001 compared with control group using ANOVA and Student–Newman–Keuls test
⁎ P≤0.05 compared with control group using ANOVA and Student–Newman–Keuls test a
⁎⁎ P≤0.01 compared with control group using ANOVA and Student–Newman–Keuls test a[ANOVA: F(8,72)=9.776, Pb0.001; Fig. 3B] was increased by EO
(500 mg/kg) (Pb0.05 vs. vehicle), β-caryophyllene (100 and
200 mg/kg) (Pb0.05 and Pb0.01 vs. vehicle, respectively) and diaze-
pam (1 mg/kg) (Pb0.001 vs. vehicle group), while diazepam
(5 mg/kg) reduced this parameter (Pb0.05 vs. vehicle group). With
regard to the total number of entries into the closed arms [ANOVA:
F(8,72)=4.153, Pb0.001; Fig. 3C], only diazepam (5 mg/kg) reduced
this parameter (Pb0.05 vs. vehicle).
3.7. Light–dark box test
In the light–dark test, the number of transitions between the light
and dark compartments [ANOVA: F(8,72)=8.760, Pb0.001; Fig. 4A]n the central area (s) Rearing Grooming Fecal bolus
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ntial oil from Spiranthera odoratissima leaves (125, 250 and 500 mg/kg, p.o.), β-car:
as the post hoc test.
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Fig. 3. Effect of essential oil (EO) from Spiranthera odoratissima leaves and β-
caryophyllene on the entries (A) and time spent (B) on open arms and total entries
in closed arms (C), as evaluated in the elevated plus maze test. Vehicle (V, 2% Tween
80, 10 mL/kg p.o.), essential oil (EO, 125, 250 or 500 mg/kg p.o.), β-caryophyllene
(50, 100 or 200 mg/kg p.o.) and diazepam (DZP, 1 or 5 mg/kg p.o.). The columns and
vertical bars represent the means±SEM of nine mice. *P≤0.05, **P≤0.01,
***P≤0.001 compared with control group using ANOVA and Student–Newman–Keuls
test as the post hoc test.
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Fig. 2. Effect of essential oil (EO) from Spiranthera odoratissima leaves on the number of
head-dipping behavior (A) and the number of squares crossed (B), as evaluated in hole-
board test. Vehicle (V, 2% Tween 80, 10 mL/kg p.o.), essential oil (EO, 125, 250 or
500 mg/kg p.o.), β-caryophyllene (50, 100 or 200 mg/kg p.o.) and diazepam (DZP, 1
or 5 mg/kg p.o.). The columns and vertical bars represent the means±SEM of nine
mice. *P≤0.05, **P≤0.01, ***P≤0.001 compared with control group using ANOVA
and Student–Newman–Keuls test as the post hoc test.
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hicle), β-caryophyllene (100 and 200 mg/kg) (Pb0.05 and Pb0.05 vs.
vehicle, respectively) and diazepam 1 mg/kg (Pb0.01 vs. vehicle),
while this parameter was reduced (Pb0.05 vs. vehicle) upon diaze-
pam (5 mg/kg) treatment. The time spent in the light compartment
[ANOVA: F(8,72)=22.698, Pb0.001; Fig. 4B] was increased by treat-
ment with EO (250 and 500 mg/kg) (Pb0.05 and Pb0.001 vs. vehicle,
respectively), β-caryophyllene (100 and 200 mg/kg) (Pb0.05 and
Pb0.05 vs. vehicle, respectively), and diazepam (1 mg/kg) (Pb0.05
vs. vehicle), while diazepam (5 mg/kg) reduced this parameter
(Pb0.05 vs. vehicle).
3.8. Mechanisms involved in the anxiolytic-like effects of EO
In both the elevated plus maze and light–dark box tests, the
anxiolytic-like effect of EO was not signiﬁcantly decreased when ﬂu-
mazenil was injected before oral administration of EO (500 mg/kg).
However, this effect was signiﬁcantly decreased whenmice were pre-
treated with NAN-190 (Figs. 5 and 6). Meanwhile, the anxiolytic-like
effect of β-caryophyllene (200 mg/kg) was not signiﬁcantly altered
by either ﬂumazenil or NAN-190 pretreatment (Figs. 5 and 6).
4. Discussion
In the current work, we examined the behavioral effects of oral
treatment with the essential oil derived from S. odoratissima leaves
and its major component, β-caryophyllene, using well-validated
animal models of CNS activity, namely the rota-rod, open-ﬁeld,
pentobarbital-induced sleep, hole-board, elevated plus maze and
light–dark box tests. We also assayed the role of GABAA/benzodiaze-
pine and 5HT1A receptors in the effects of EO and β-caryophyllene
effects.The effects on general behavioral test observed upon EO treat-
ment, such as decreased spontaneous ambulation, presence of anal-
gesia, environmental alienation and palpebral ptosis are suggestive
of central depressant drugs. This methodology indicates the optimal
route and doses for other in vivo biological tests. The group of mice
that was treated with these compounds orally exhibited an absence
of deaths and behaviors suggestive of neurotoxicity throughout the
observational period, making this route the most promising for further
evaluations using doses up to 1000 mg/kg. Therefore, we chose doses of
125, 250 and 500 mg/kg for further tests aimed at assaying possible
anxiolytic-like effects and verifying a dose–response relationship.
A deﬁcit in motor coordination would very likely affect perfor-
mance in the behavioral tests. Therefore, we investigated the motor
effects of EO in the rota-rod test, a classical animal model used to
evaluate peripheral neuromuscular blockade and the motor coordina-
tion (Dunham and Miya, 1957). Our ﬁndings showed that EO
(125–500 mg/kg), unlike diazepam (5 mg/kg), had no signiﬁcant ef-
fect on motor coordination (Table 1).
The open-ﬁeld test is designed to study exploratory activity
(Crawley, 1985); in this test, EO administration did not alter the
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Fig. 4. Effect of essential oil (EO) from Spiranthera odoratissima leaves and β-
caryophyllene on transitions number (A) and time spent in light compartment
(B), as evaluated in the light–dark box test. Vehicle (V, 2% Tween 80, 10 mL/kg p.o.), es-
sential oil (EO, 125, 250 or 500 mg/kg p.o.), β-caryophyllene (50, 100 or 200 mg/kg
p.o.) and diazepam (DZP, 1 or 5 mg/kg p.o.). The columns and vertical bars represent
the means±SEM of nine mice. *P≤0.05, **P≤0.01, ***P≤0.001 compared with control
group using ANOVA and Student–Newman–Keuls test as the post hoc test.
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Fig. 5. Inﬂuence of the pretreatment with ﬂumazenil or NAN-190 on the anxiolytic-like
effect of essential oil (EO) from Spiranthera odoratissima leaves and β-caryophyllene on
the entries (A) and time spent (B) on open arms and total entries in closed arms (C), in
the elevated plus maze test. Control (C, 2% Tween 80 10 mL/kg i.p. and p.o.), essential
oil (EO, 500 mg/kg p.o.), β-caryophyllene (β-car, 200 mg/kg p.o.), vehicle (V, 2% Tween
10 mL/kg i.p.), NAN-190 (NAN, 0.5 mg/kg i.p.) and ﬂumazenil (Flu, 6 mg/kg i.p.). The
columns and vertical bars represent the means±SEM of nine mice. *P≤0.05, **P≤0.01
compared with control group using unpaired “t” test. #P≤0.05, # #P≤0.01 compared
with OE or β-car group using unpaired “t” test.
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motor coordination previously observed in the rota-rod test. The de-
crease in rearing behavior seems to be unrelated to a loss of motor co-
ordination or to neuromuscular blockade; instead, it may be caused
by a central depressant activity. EO treatment also increased the pref-
erence for the central area, enhancing the crossing number and the
time spent in the central area of the apparatus (Table 2); an increase
in these parameters could be indicative of anxiolytic-like effects (Prut
and Belzung, 2003). EO, at all doses tested, reduced the fecal bolus
(Table 2). Because defecation is a good indicator of emotionality in
animals, its reduction can be associated with an anxiolytic-like effect;
however, it can also be attributed to other physiological factors not
associated with anxiety states (Angrini et al., 1998; Archer, 1973).
The pentobarbital-induced sleep test was assessed to conﬁrm the
putative depressant-like effects observed in the previous tests. In
this test, CNS depressant drugs classically decrease the sleep latency
and increase the sleeping time (Carlini and Burgos, 1979); EO showed
both effects, conﬁrming its depressant-like effect (Fig. 1). This EO CNS
depressant-like effect could be due to anxiolytic-like properties; to
verify this hypothesis, we used the hole-board, elevated plus maze
and light–dark box tests.
The hole-board test is useful for modeling anxiety in animals; in
this test the expression of an anxiolytic-like state may be reﬂected
by an increase in head-dipping behaviors (Crawley, 1985; Takeda
et al., 1998). Our results showed that EO increased the number of
head dips without altering the number of squares crossed (Fig. 2) in-
dicating an anxiolytic-like effect without any change in locomotion.
The elevated plus maze test is one of the most widely employed
tests for evaluation of anxiolytic/anxiogenic properties. This test is
based on the observation that the natural behavior of rats or mice is
to display an aversion to open spaces; therefore, avoidance of the
open arms is interpreted as anxiogenic behavior (Belzung andGriebel, 2001; Bertoglio and Carobrez, 2005). The anxiolytic-like ef-
fectiveness of a drug can be demonstrated by an increase in explora-
tion of the open arms (time and entries into open arms), while the
opposite holds true for drugs with anxiogenic-like effects (Bertoglio
and Carobrez, 2005; Lister, 1987; Rodgers and Cole, 1994). The num-
ber of closed arm entries provides a control measure of motor activity
(Bourin et al., 2007). In the present study, EO increased the entries
into and time spent in the open arms without altering the number
of entries into closed arms (Fig. 3), indicating an anxiolytic-like effect
without motor impairment.
In the light–dark box test, anxiety is generated by the conﬂict be-
tween the desire to explore and to retreat from an unknown and
well-illuminated space (Crawley and Goodwin, 1980) and can be
evaluated according to the number of transitions into and the time
spent in the light chamber (Graeff and Zangrossi, 2002; Lepicard
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Fig. 6. Inﬂuence of the pretreatment with ﬂumazenil or NAN-190 on the anxiolytic-like
effect of essential oil (EO) from Spiranthera odoratissima leaves and β-caryophyllene on
transitions number (A) and time spent in the light compartment (B), in light–dark box
test. Control (C, 2% Tween 80 10 mL/kg i.p. and p.o.), essential oil (EO, 500 mg/kg p.o.),
β-caryophyllene (β-car, 200 mg/kg p.o.), vehicle (V, 2% Tween 80 10 mL/kg i.p.), NAN-
190 (NAN, 0.5 mg/kg i.p.) and ﬂumazenil (Flu, 6 mg/kg i.p.). The columns and vertical
bars represent the means±SEM of nine mice. *P≤0.05, **P≤0.01 compared with control
group using unpaired “t” test. #P≤0.05, # #P≤0.01 comparedwithOEorβ-car group using
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reﬂect anxiolytic-like properties. Our results showed that EO treat-
ment increased these two parameters (Fig. 4), corroborating the
anxiolytic-like effect previously shown in the hole-board and elevat-
ed plus maze tests. Therefore, the results obtained in these three
methods show that EO has an anxiolytic-like activity without the
motor impairment characteristic of sedative effects.
Benzodiazepines are the most widely prescribed CNS depressants,
with selective activity at the inhibitory GABAA receptor complex; they
act to potentiate the inhibitory effect of GABA by enhancing the fre-
quency of chloride channel opening and thus enhance the chloride
ﬂux through the GABAA receptor/chloride channel (Lilly and Tietz,
2000). As expected, diazepam (1 mg/kg) produced an anxiolytic-like
effect while diazepam (5 mg/kg) produced motor impairment.
To determine if the mechanism underlying the anxiolytic-like ef-
fects of EO involves the benzodiazepine system, we pretreated the an-
imals with ﬂumazenil, a well-known competitive antagonist that
binds the benzodiazepine site of the GABAA receptor, at a dose that
antagonizes the anxiolytic effects of diazepam in the elevated plus
maze and light–dark box tests (data not shown). Our results show
that the effects of EO were not signiﬁcantly altered by ﬂumazeniltreatment (Figs. 5 and 6), indicating that EO's anxiolytic-like effects
do not involve the benzodiazepine site of the GABAA receptor.
The 5-hydroxytryptamine 1A (5-HT1A) receptor is a potential tar-
get for the treatment of psychiatric disorders, notably anxiety and de-
pression (File, 1996). This receptor is a Gi-coupled-receptor that,
when activated, inhibits adenylyl cyclase activity and enhances K+
currents (Raymond et al., 1999). 5-HT1A receptors are located at pre-
synaptic and postsynaptic sites (Blier et al., 1993). Buspirone, an anxi-
olytic drug with partial agonist properties at this receptor, has
efﬁcacy in the treatment of patients with Generalized Anxiety Disor-
der (GAD) (Goa and Ward, 1986; Graeff et al., 1996), and a meta-
analysis has indicated that buspirone has comparable efﬁcacy to ben-
zodiazepines in the management of GAD (Gammans et al., 1992).
Therefore, the 5-HT1A receptor is a pharmacological target that
could be relevant to the mechanism of action of EO. Additionally,
the anxiolytic drugs that act on the 5-HT1A receptor are known as
“anxioselective” because they do not possess the side effects com-
monly caused by benzodiazepine treatment, such as motor impair-
ment and a decrease in spontaneous locomotion in animals (Harada
et al., 2006; Siemiatkowski et al., 2000; Stefanski et al., 1992).
The possible involvement of the 5-HT1A receptor complex in EO's
mechanism of action was also tested in the elevated plus maze and
light–dark box tests. EO's anxiolytic-like effects were antagonized
by NAN-190 (Figs. 5 and 6), a 5-HT1A receptor antagonist. Therefore,
the EO anxiolytic-like activity seems to be mediated via 5-HT1A
receptor activation.
Recently, Foong and Bornstein (2009) found that NAN-190 may
also block α2-adrenoceptors, raising a concern about the selectivity
of NAN-190 for the 5-HT1A receptors and suggesting that EO's effects
may be partially mediated by α2-adrenoceptors.
Celedônio (2008) showed that β-caryophyllene, the major com-
ponent of EO, has anti-nociceptive effects in the hot plate and
formalin- and glutamate-induced pain tests, tests, which are sensitive
to CNS drugs. Thus, it is probable that β-caryophyllene is active in CNS
when administered orally. Therefore, this compound was tested to
verify if it has anxiolytic-like effects similar to those of EO and if it
shares the same mechanism of action.
Using the rota-rod test (Dunham and Miya, 1957), we assessed the
motor coordination of animals treated with β-caryophyllene (100, 200
or 400 mg/kg). Galindo et al. (2010) observed that β-caryophyllene, at
doses of up to 50 mg/kg p.o., does not producemotor impairment; in ac-
cordance with this result, we showed that this compound, at doses of up
to 400 mg/kg p.o., does not produce motor impairment (Table 1).
β-Caryophyllene was then tested in the pentobarbital-induced
sleep test (Carlini and Burgos, 1979). Galindo et al. (2010) showed
that β-caryophyllene (at doses of up to 50 mg/kg) has no effect in
this test; our results are in accordance with this, given that in our
hands the 100 mg/kg dose has no effect. However, the 200 and
400 mg/kg doses decreased the latency and increased the sleep
time; these effects were similar to, albeit less pronounced than,
those of EO (Fig. 1). Galindo et al. (2010) have also suggested that
even at subactive doses this compound may increase the depressive
effect of other substances.
In the anxiety tests, β-caryophyllene (100 and 200 mg/kg) had
anxiolytic-like effects, increasing the head-dipping behavior in the
hole-board test (Fig. 2) and the exploration in the open arms of the
EPM (Fig. 3A and B) and in the light area of the LDB (Fig. 4), without
demonstrating evidence of motor impairment in the EPM (Fig. 3C). It
is noteworthy that the anxiolytic-like dose of β-caryophyllene
(100 mg/kg) is proportional to the anxiolytic-like dose of EO
(500 mg/kg), suggesting that β-caryophyllene may contribute to the
effects of EO; however, the effectiveness of β-caryophyllene was sim-
ilar to or less than the effectiveness of EO.
After determining that β-caryophyllene has an anxiolytic-like ac-
tivity, the possible mechanisms of action were studied, speciﬁcally
by evaluating the role of GABAA/benzodiazepine and 5-HT1A
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the antagonists was able to antagonize the anxiolytic-like effects ob-
served (Figs. 5 and 6), suggesting that non-GABAA/benzodiazepine,
non-5-HT1A receptors are involved.
The identiﬁcation of the effects of the major component contrib-
utes to the standardization of the herbal preparation and safeguards
the quality and the reproducibility of EO's effects; however, in this
case this compound does not have the same mechanism of action as
EO. This implies that this component likely is not the most important
determinant of the anxiolytic-like effect that involves the serotoner-
gic system; however, it may act to increase the effects of other com-
pounds, as suggested by Galindo et al. (2010).
In the literature, there are no studies regarding other EO compo-
nents. Only β-caryophyllene has been evaluated in various pharmaco-
logical tests, which commonly demonstrate its analgesic and anti-
inﬂammatory properties (Celedonio, 2008; Fernandes et al., 2007;
Medeiros et al., 2007; Passos et al., 2006). To our knowledge, this is
the ﬁrst study of the anxiolytic-like effects of β-caryophyllene.
Recently, Gertsch et al. (2008) demonstrated that β-caryophyllene
binds selectively to cannabinoid receptor 2 and acts as a full agonist.
Cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptors are GTP-
binding protein (G-protein) coupled receptors that were ﬁrst cloned
in the early 1990s (Matsuda et al., 1990; Munro et al., 1993). Some re-
ports have suggested that the serotonergic system can be modulated
by the cannabinoid system via the CB1 receptor (Bambico et al., 2007;
Haj-Dahmane and Shen, 2011; Lau and Schloss, 2008; McLaughlin
et al., 2009).
For a long time it was believed that the CNS expresses only CB1, but
studies have demonstrated the presence of CB2 in various CNS struc-
tures, including the spinal cord, microglial cultures, brainstem and
cortex (Morgan et al., 2009; Onaivi et al., 2006). CB2 has become an at-
tractive therapeutic target because this receptor has not been associ-
ated with CNS side effects caused by CB1 activation (Gertsch et al.,
2008). Recent results frommicewith geneticallymodiﬁed CB2 suggest
that CB2 signaling is involved in the regulation of emotional behaviors
including anxiety (Marco et al., 2011); thus, the cannabinoid system
may be involved in the anxiolytic-like effects of β-caryophyllene.
The possibility of using a preparation (the essential oil) that acts on
two systems (serotonergic and cannabinoid)maywiden the spectrum
of cellular targets, thus resulting in a more favorable clinical effect.
Overall, beneﬁcial results can be obtained with drugs or plant spe-
cies with proven efﬁcacy in the treatment of GAD (Faustino et al.,
2010; Sousa et al., 2008); therefore, the use of OE may represent a
new therapeutic option in the treatment of GAD, a hypothesis needs
to be better evaluated and proved in clinical studies.
5. Conclusions
EO and β-caryophyllene show anxiolytic-like effects without alter-
ing motor coordination, and β-caryophyllene may contribute to the
effects of EO. EO's anxiolytic-like effects seem to be mediated by 5-
HT1A receptors, while the anxiolytic-like effects of β-caryophyllene
seem to be independent of 5-HT1A and benzodiazepine receptors.
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